Massive Bio, Mika Health Blend AI with Digital Therapy to Boost Cancer Trial Access

Massive Bio and Mika Health, two leading AI-enabled healthcare technology companies, announced a partnership aimed at enhancing access to clinical trials, biomarker testing, and digital therapeutics for cancer patients.

The collaboration will allow patients receiving treatment through Mika Health’s personalized oncology digital therapeutic platform to opt into Massive Bio’s AI-powered clinical trial matching system and next-generation sequencing (NGS) biomarker testing eligibility engine. Conversely, Massive Bio will provide free access to Mika Health’s digital therapy to its registry of hundreds of thousands of cancer patients.

“Patients waiting to find and access effective cancer treatments face tremendous challenges, both physical and mental,” said Dr. Gandolf Finke, CEO and Founder of Mika Health. “Our partnership with Massive Bio will help more patients access genomic testing, get matched to suitable clinical trials faster, and receive essential psycho-oncological support – ultimately improving outcomes and experiences.”

Despite evidence showing the benefits of NGS biomarker testing in dictating cancer survivorship, its utilization remains low, with less than 50% of eligible lung cancer patients receiving the standard-of-care testing in the U.S. and Europe.

“By combining our AI expertise with Mika Health’s comprehensive digital therapy, we can significantly enhance cancer patient outcomes and access to innovative therapies and much-needed support,” remarked Dr. Selin Kurnaz, Co-Founder and CEO of Massive Bio.

The partnership aims to streamline clinical trial enrollment, reduce manual effort, and ultimately improve treatment options and outcomes through data-driven insights into patient experiences and real-world evidence.

“Integrating our platforms will empower patients and oncologists with the support patients desperately need as they seek personalized and accessible treatments,” said Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer of Massive Bio. “It will also expand awareness and utilization of biomarker and genomic testing when appropriate.”

As cancer treatments become more personalized, this collaboration between Mika Health and Massive Bio positions itself as a crucial step toward closing the access gap, raising the standard of care quality, and accelerating time to the right treatment for patients.